R.J. Reynolds Tobacco Co. v. United States Food & Drug Administration

Tobacco companies challenged the composition of the Tobacco Products Scientific Advisory Committee (TPSAC), which was established by the U.S. Food and Drug Administration (FDA) to advise the agency on scientific issues related to tobacco products, including the use of menthol in cigarettes. The tobacco companies alleged that three of the scientific members of the Committee had both an actual and a perceived conflict of interest because each consulted with companies that developed nicotine replacement therapies and testified as expert witnesses in lawsuits against tobacco manufacturers. The district court ruled in favor of the tobacco companies, finding that the challenged committee members had both financial conflicts of interest and an appearance of conflicts of interest, which fatally tainted the composition of the Committee and its work product, including the 2011 Committee report on menthol in cigarettes. The district court issued an order requiring the FDA to reconstitute the Committee’ membership to comply with ethics laws and barred the agency from using the Committee’s menthol report, which had recommended removing menthol cigarettes from the marketplace.  The FDA appealed, and a three-judge panel of the appeals court unanimously reversed the lower court ruling, finding that plaintiffs had not shown imminent injury from the appointment or the actions of challenged Committee members.

The Campaign for Tobacco-Free Kids, joined by seventeen other public health and medical groups, filed an amicus brief urging reversal of the district court decision.

R.J. Reynolds Tobacco Company, et al. v. United States Food and Drug Administration, et al., No. 14-5226 (D.C. Cir. January 15, 2016).

  • United States
  • Jan 15, 2016
  • U.S. Court of Appeals for the District of Columbia Circuit

Parties

Plaintiff United States Food and Drug Administration

Defendant

  • Lorillard Tobacco Company
  • R.J. Reynolds Tobacco Company
  • R.J. Reynolds Tobacco Holdings, Inc.

Legislation Cited

Related Documents

Type of Litigation

Tobacco Control Topics

Substantive Issues

Type of Tobacco Product

None

"Plaintiffs claim that the FDA’s appointments of these Committee members caused them three injuries: (1) an increased risk that the FDA will regulate menthol tobacco products adversely to plaintiffs’ interests; (2) access by the challenged Committee members to plaintiffs’ confidential information, with a probability of their using the information to plaintiffs’ detriment; and (3) the shaping of the menthol report to support the challenged members’ consulting and expert witness businesses, with injuries flowing both from the report itself and from its use as support for their expert testimony and consulting...Under the familiar threefold inquiry, plaintiffs must show an injury-in-fact that is “actual or imminent, not conjectural or hypothetical,” and must show causation and redressability. Lujan v. Defenders of Wildlife, 504 U.S. 555, 560-61 (1992) (internal citations and quotation marks omitted). At summary judgment, plaintiffs cannot rest on “‘mere allegations’ but must ‘set forth’ by affidavit or other evidence ‘specific facts.’” Id. at 561 (quoting FED. R. CIV. P. 56(e)). Addressing the three alleged injuries in the order already presented, we conclude that all three are too remote and uncertain, or, to put the same thing another way, insufficiently imminent. We therefore vacate the district court’s grant of summary judgment."